MX2021013386A - Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas. - Google Patents

Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas.

Info

Publication number
MX2021013386A
MX2021013386A MX2021013386A MX2021013386A MX2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A
Authority
MX
Mexico
Prior art keywords
indigo
compositions
methods
derivative
treatment
Prior art date
Application number
MX2021013386A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Davidson
Julie Saiki
Johan Andreasson
Michael David Favero
Matthew Benjamin Greene
Original Assignee
Azora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azora Therapeutics Inc filed Critical Azora Therapeutics Inc
Publication of MX2021013386A publication Critical patent/MX2021013386A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013386A 2019-05-03 2020-05-01 Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas. MX2021013386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021013386A true MX2021013386A (es) 2022-03-22

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013386A MX2021013386A (es) 2019-05-03 2020-05-01 Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas.

Country Status (10)

Country Link
US (3) US20200345645A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962458A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022531012A (cg-RX-API-DMAC7.html)
KR (1) KR20220044435A (cg-RX-API-DMAC7.html)
CN (1) CN114340600A (cg-RX-API-DMAC7.html)
AU (1) AU2020269379A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136081A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021013386A (cg-RX-API-DMAC7.html)
TW (1) TW202106296A (cg-RX-API-DMAC7.html)
WO (1) WO2020227151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TWI836752B (zh) 2021-11-30 2024-03-21 美商安督奎斯特機器人公司 用於機器人控制醫療裝置的力傳輸系統
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases
KR20250069676A (ko) * 2022-10-10 2025-05-19 더데르마 상하이 컴퍼니 리미티드 궤양 예방 및/또는 치료를 위한 스틸벤 유도체의 용도
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス,インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス,インコーポレーテッド インジルビン固体分散体組成物
TWI737602B (zh) 2015-04-09 2021-09-01 瑞士商高德美公司 藥學組合物及其製劑
CA3021071A1 (en) * 2016-04-19 2017-10-26 Ferring B.V. Oral pharmaceutical compositions of mesalazine
WO2019142799A1 (ja) * 2018-01-18 2019-07-25 学校法人慶應義塾 潰瘍性大腸炎治療カプセル剤

Also Published As

Publication number Publication date
KR20220044435A (ko) 2022-04-08
JP2022531012A (ja) 2022-07-05
US20250255820A1 (en) 2025-08-14
TW202106296A (zh) 2021-02-16
CN114340600A (zh) 2022-04-12
EP3962458A1 (en) 2022-03-09
WO2020227151A1 (en) 2020-11-12
US20220249382A1 (en) 2022-08-11
US20200345645A1 (en) 2020-11-05
CA3136081A1 (en) 2020-11-12
AU2020269379A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2022003782A2 (es) Inhibidores de kras g12d
JOP20200278B1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
ZA201906822B (en) Indole ahr inhibitors and uses thereof
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
UY38403A (es) Moduladores de la alfa-1 antitripsina
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MY196582A (en) PD-1/PD-L1 Inhibitors
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
BR112019023290A2 (pt) Tienopiridinas e benzotiofenos úteis como inibidores de irak4
CL2015003569A1 (es) “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct
MX2025010681A (es) Formulaciones transdermicas
MX390083B (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
EA201892200A1 (ru) Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
CO2020001325A2 (es) Combinaciones herbicidas sinérgicas
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
CL2019002840A1 (es) Formas cristalinas de (s)-afoxolaner.